Press Release

ShedRx Announces Availability of Name-Brand Weight-Loss Medications Wegovy®, Ozempic®, and Mounjaro®

ShedRx Expands Weight-Loss Solutions with FDA-Approved Medications Wegovy®, Ozempic®, and Mounjaro® for Personalized Health and Wellness

Syringe leaning on a clear glass container filled with medication
Salt Lake City, UT / Feb 25, 2025 / ShedRx

ShedRx, a trusted leader in personalized weight-loss solutions, is excited to announce the availability of name-brand weight-loss medications Wegovy®, Ozempic®, and Mounjaro® to help individuals take control of their health and achieve their weight-loss goals.

Wegovy® and Ozempic® are prescription medications that contain semaglutide, a GLP-1 receptor agonist, which works by helping regulate appetite, improve blood sugar control, and promote sustainable weight loss. Mounjaro® is a prescription medication that contains tirzepatide which includes both a GLP-1 receptor agonist and another metabolic hormone called GIP. This has shown to be highly effective for weight loss and may even provide fewer side effects than semaglutide for some patients.

These FDA-approved treatments have gained significant recognition for their effectiveness in supporting individuals on their weight-loss journey, with Wegovy® specifically designed for weight management and Ozempic® and Mounjaro® originally developed for type 2 diabetes management.

ShedRx is proud to offer these well-known, high-quality medications as part of its comprehensive weight-loss and wellness services. With the support of our team of healthcare professionals, patients can receive personalized treatment plans tailored to their needs and lifestyle.

Key benefits of Wegovy®, Ozempic®, and Mounjaro® include:

  • Appetite Regulation: They help reduce hunger and promote portion control.
  • Sustained Weight Loss: Clinical studies show that semaglutide can lead to significant weight loss when combined with healthy diet and exercise.
  • Blood Sugar Management: Ozempic® is designed to help regulate blood sugar levels for those with type 2 diabetes.

“We are thrilled to offer Wegovy®, Ozempic®, and Mounjaro® to our patients,” said Morley Baker, founder and CEO of ShedRx. “These medications are changing the way people approach weight loss and with our personalized coaching support and GLP-1 co-pilots, we can help individuals maximize their success in a safe and sustainable way.”

At ShedRx, patients are empowered with the knowledge and tools to make lasting lifestyle changes, supported by a team of medical professionals who understand the importance of individualized care.

For more information on Wegovy®, Ozempic®, Mounjaro®, or to schedule a consultation through ShedRx to meet with a healthcare provider, please visit shedrx.com

*Ozempic® and Wegovy® are trademarks of Novo Nordisk A/S. Mounjaro® is a registered trademark of Eli Lilly and Co., d/b/a Lilly. ShedRx has no ownership over brand-name, FDA-approved medications or products.

To learn more about Novo Nordisk products, please visit https://www.novonordisk.com/our-products/our-medicines.html.

To learn more about Lilly products, please visit https://www.lilly.com/our-medicines/current-medicines.

###
About ShedRx

ShedRx is a health and wellness brand dedicated to helping individuals unlock their best selves through premium nutrition products, health and wellness coaching, and weight-loss medication. With a focus on high-quality ingredients and effective formulations, Shed empowers people to take charge of their health and achieve their wellness goals, while helping them each step of the way.

Press Contact
Jamie Neider
jamie@shedrx.com
ShedRx
Strategic intelligence for the future of health.

We break down how fitness, wellness, and healthcare are converging — and what it means for business, culture, and capital.

No thanks.